Tag
AI is transforming both ends of cancer care: Recursion's REC-617 became the first AI-designed drug to shrink tumors in a patient within 12 months, AI-assisted mammography found 30% more cancers in a 100k-person Swedish trial, and AlphaFold uncovered a hidden cell-transport switch (AVL9) that turns out to be an off-switch for cancer metastasis. Yet no AI-designed cancer drug is approved, and the historic 90% clinical trial failure rate remains unbroken.
Enveda, a biotech startup using AI for nature-based drug discovery, has raised $311 million in Series E funding to advance its drug candidates into clinical trials.
Anthropic has quietly established a biology lab to advance its AI-driven drug discovery program.
An experimental AI-created drug, Rentosertib, unexpectedly reduced patients' biological age indicators by about 6 years during trials for idiopathic pulmonary fibrosis.
This newsletter edition covers two tech stories: the potential night sky disruption from Reflect Orbital's space mirrors and the intellectual property dilemmas when AI designs drugs, as seen with Insilico Medicine's patent practices.
The article discusses how AI is used in drug discovery but patent laws require human inventors, raising tensions between technological advancement and intellectual property rights.
Biotech startup Vivodyne claims current AI models lack sufficient human tissue data for effective drug discovery and has developed robotic labs called HIVE to generate this data, aiming to improve preclinical testing for diseases like cancer.
Reed Jobs, son of Steve Jobs, manages a $1B+ VC firm called Yosemite that invests in cancer research and biotech, including AI drug discovery and gene editing, with the goal of making cancer non-lethal.
GSK expands its $110M AI drug discovery partnership with Relation Therapeutics, emphasizing that clean, disease-specific biological data from lab experiments is more valuable than larger models. The move highlights an industry-wide pivot toward proprietary data as a competitive moat in AI-driven pharma.
AstraZeneca uses AI to generate and rank protein candidates, integrating models with experiments and robotics to speed up biologic drug discovery and tackle previously undruggable targets.
AI is accelerating biologic drug design by predicting candidate molecules and enabling multi-target therapies, with potential to cut discovery timelines by 50% and target previously undruggable diseases.
This paper proposes JoPMol, a jointly controlled precision molecular generative model that integrates gene expression profiles, molecular structure text, and chemical properties to generate personalized drug candidates, outperforming state-of-the-art methods.
CAPABLE is an AI-driven lab that can go from drug design to data in 24 hours, starting with short-sleeper peptides. The project aims to turn AI capabilities into human capabilities for drug development.
Anthropic announced Claude Science, an AI workbench for scientists, and revealed its own plans to develop drugs for neglected diseases using AI, entering a competitive field of AI-driven drug discovery.
Anthropic is launching an internal AI drug discovery program to develop treatments for neglected diseases, aiming to improve its AI tools for drugmakers and join tech giants in the healthcare market.
The article profiles chemist Tim Cernak, who applies AI-driven drug design (like AlphaFold) to develop precision treatments for wildlife, coining the field 'conservation chemistry' to address mass extinction with cutting-edge tools.
DeepMind's Co-Scientist AI helped identify two repurposed medicines that block liver fibrosis in lab tests, including a cancer drug that blocked 91% of a damage response, outperforming human expert selections.
Demis Hassabis claims AI can cure all diseases within 10 years, backed by a $2.1B funding round for Isomorphic Labs to accelerate AI-driven drug discovery and personalized medicine.
Isomorphic Labs, an AI-driven drug discovery company founded by Demis Hassabis, announced a $2.1 billion Series B funding round led by Thrive Capital to scale its business and advance its AI drug design engine, IsoDDE.
Dell Technologies highlights how AI is accelerating drug discovery and improving patient outcomes through their AI Factory partnership with NVIDIA, offering tailored solutions for enterprise adoption.